Deep Learning Model Using Contrast-Enhanced CT to Predict Disease-Free Survival in Localized Clear Cell Renal Cell Carcinoma
Led by Mingzhao Xiao · Updated on 2025-05-31
800
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a deep learning model based on contrast-enhanced CT images to predict disease-free survival DFS before surgery in patients with localized clear cell renal cell carcinoma ccRCC. This study aims to validate the models predictive ability using data from multiple centers and compare its performance with traditional prediction methods. The study focuses on patients who have undergone nephrectomy and have confirmed ccRCC diagnosis.
The study involves reviewing preoperative CT images and clinical data of patients who had partial or radical nephrectomies for ccRCC. Participants are categorized into groups based on recurrence status, with the deep learning model assessing risk of disease recurrence. The models ability to predict DFS is compared to that of existing conventional models using retrospective data collected between June 2013 and March 2020.
Participants contribute by providing their preoperative CT images and clinical information for analysis. Researchers measure disease-free survival as the primary outcome to assess model accuracy. The study does not involve treatment interventions or active follow-up but relies on existing data. The total study period extends until August 2025, allowing comprehensive validation of the model across multiple centers.
CONDITIONS
Brief Title
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologically diagnosed with clear cell renal cell carcinoma (ccRCC)
Have complete clinical data and preoperative contrast-enhanced CT image data available
You will not qualify if you...
Incomplete clinic-pathological data
Lack of preoperative contrast-enhanced CT images or images unsuitable for analysis
Received neoadjuvant or adjuvant therapies before surgery
Have multiple renal tumors or synchronous metastasis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Varies depending on scheduling before surgery
Participants undergo preoperative contrast-enhanced CT scans and clinical data collection before surgery.
1 to 2 visits depending on imaging and clinical assessments
Surgery
Duration - Hospital stay duration as per routine care
Participants undergo partial or radical nephrectomy surgery for localized clear cell renal cell carcinoma.
1 visit (surgery day)
Long-term Monitoring
Duration - Up to several years post-surgery until study completion
Participants are observed to assess disease-free survival following surgery.
Follow-up visits scheduled as per routine clinical care
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Study of 68Ga-C1 PETCT Imaging Compared to 18F-FDG PETCT for Diagnosing Clear Cell Renal Cell Carcinoma in Adults
Study of Radiation Therapy Guided by 68Ga-NY104 and 18F-FDG PETCT Combined with Systemic Treatment for Patients with Clear Cell Renal Cell Carcinoma
Phase 3 Study of 89Zr-TLX250 PETCT Imaging to Detect Clear Cell Renal Cell Carcinoma in Chinese Adults with Indeterminate Renal Masses
Exploratory Study of 18FPT2385 PETCT Imaging to Measure HIF2lpha in Patients with Renal Cell Carcinoma including Metastatic and Von Hippel-Lindau Syndrome Cases
Phase 12 Study of MDNA11, a Beta-only IL-2 Therapy, Alone or With Pembrolizumab for Advanced Solid Tumors
Phase 1 Study to Assess Safety and Effects of AB521 Alone and With Other Drugs in Advanced Clear Cell Renal Cell Carcinoma and Solid Tumors
Phase 11b Study of MGC026 Given by IV Infusion in Adults With Advanced or Metastatic Solid Tumors
Phase 1 Study of NN3201, a c-Kit Targeting Antibody-Drug Combination, for Advanced or Metastatic Solid Tumors Expressing c-Kit
Evaluation of PD-32766D and PD-32766T in Adults with Relapsed or Refractory CA9-Positive Clear Cell Renal Cell Carcinoma
Effect of Adding CBM588 to Pembrolizumab on Preventing Recurrence in High-Risk Renal Cell Cancer After Surgery
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Three-dimensional deep learning model complements existing models for preoperative disease-free survival prediction in localized clear cell renal cell carcinoma: a multicenter retrospective cohort study.